Quantitation of an individual CMV peptide-specific CTL clone within CD45RA^high and CD45RO^high CD8+ T-cell subpopulations derived from PBMC of a donor during and after primary CMV infection.

(A) Duplicate TCR Vβ6.4 PCR products were amplified from each of the T cell populations taken at 3, 4, 8 and 37 weeks after onset of symptoms. PCR product derived from the biological pp65 peptide 56-specific clone (positive control) and pooled PCR product derived from PBMC of four CMV seronegative donors (negative control) were probed with a radio-labelled clonotypic probe. (B) The filter was stripped of bound clonotypic probe and re-probed with a radiolabelled probe specific to the TCR constant region. For each sub-population, the clonotype sequence as a % of all TCR Vβ6.4⁺ sequences is shown for 2 independent amplifications and probing experiments, % in bold are derived from the gel shown (^* duplicate PCR sample failed).